Matrix Asset Advisors Inc. NY Sells 90,174 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Matrix Asset Advisors Inc. NY reduced its stake in Zimmer Biomet by 75%, selling 90,174 shares in Q4 and now holds 30,032 shares valued at about $2.7 million.
• Zimmer Biomet slightly beat quarterly estimates (EPS $2.42 vs. $2.38; revenue $2.24B vs. $2.22B), with revenue up 10.9% YoY and FY2026 guidance of EPS 8.30–8.45 (consensus ~8.22).
• Analyst sentiment is mixed: MarketBeat reports an average rating of "Hold" with a $106.20 target, while firms including UBS and Goldman Sachs have issued recent sell downgrades.

Matrix Asset Advisors Inc. NY lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 75.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 30,032 shares of the medical equipment provider's stock after selling 90,174 shares during the quarter. Matrix Asset Advisors Inc. NY's holdings in Zimmer Biomet were worth $2,700,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Key Financial Inc increased its position in Zimmer Biomet by 164.6% in the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 163 shares during the period. Cullen Frost Bankers Inc. lifted its holdings in shares of Zimmer Biomet by 66.7% during the third quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider's stock worth $29,000 after purchasing an additional 116 shares during the period. Cary Street Partners Investment Advisory LLC grew its stake in shares of Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider's stock worth $30,000 after purchasing an additional 149 shares during the last quarter. Root Financial Partners LLC acquired a new stake in Zimmer Biomet in the third quarter valued at $31,000. Finally, Mather Group LLC. acquired a new stake in Zimmer Biomet in the third quarter valued at $36,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. UBS Group reaffirmed a "sell" rating and set a $89.00 target price on shares of Zimmer Biomet in a report on Wednesday, February 11th. The Goldman Sachs Group cut Zimmer Biomet from a "neutral" rating to a "sell" rating and set a $93.00 price target for the company. in a research note on Friday, January 9th. William Blair initiated coverage on Zimmer Biomet in a research report on Friday, February 20th. They set a "market perform" rating for the company. BTIG Research reaffirmed a "neutral" rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Finally, Weiss Ratings downgraded shares of Zimmer Biomet from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Monday, March 23rd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have assigned a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, Zimmer Biomet has an average rating of "Hold" and an average target price of $106.20.

Zimmer Biomet Price Performance

ZBH stock opened at $91.13 on Thursday. The company has a quick ratio of 1.10, a current ratio of 1.98 and a debt-to-equity ratio of 0.55. The firm has a market cap of $17.83 billion, a price-to-earnings ratio of 25.74, a PEG ratio of 1.85 and a beta of 0.61. The company's fifty day simple moving average is $92.18 and its 200 day simple moving average is $93.79. Zimmer Biomet Holdings, Inc. has a 12-month low of $84.59 and a 12-month high of $114.44.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.04. The firm had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business's quarterly revenue was up 10.9% on a year-over-year basis. During the same period last year, the company posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet's payout ratio is presently 27.12%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the business's stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares of the company's stock, valued at approximately $967,803.84. The trade was a 20.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.39% of the company's stock.

About Zimmer Biomet

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.